1 / 2

Severe Hypoglycemia Market

DelveInsight's "Severe Hypoglycemia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Severe Hypoglycemia , historical and forecasted epidemiology as well as the Severe Hypoglycemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<br><br>

yashb
Download Presentation

Severe Hypoglycemia Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. What is Severe Hypoglycemia? delveinsight20.wordpress.com/2021/07/05/what-is-severe-hypoglycemia July 5, 2021 The use of glucagon also has the potential to confer economic advantages and to free up health care resources by reducing the number of patients who have to be admitted to the hospital with severe hypoglycemia. Currently, various glucagon kits are available in the market as the Glucagon Emergency Kit (Eli Lilly) and the GlucaGenHypokit (Novo Nordisk A/S), which can be administered by IM or SC injection. 1 mg dose of glucagon (reconstituted in 1 mL of sterile water) is recommended for adults and children over 25 kg in weight; half dose (0.5 mL) is recommended for children below 25 kg in weight or younger than 6–8 years. If the patient does not respond immediately after receiving glucagon, medical help should be sought, and IV glucose administered as soon as possible. In September 2019, GvokeHypoPen (Xeris Pharmaceuticals) was approved by the US FDA for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. It is a ready-to-use, room-temperature-stable, liquid glucagon inside a single-use auto-injector pen in 2 pre-measured doses (0.5 mg and 1 mg) developed using XeriSol technology. 1/2

  2. There is currently a lack of consensus regarding the threshold blood glucose levels that classify different stages of hypoglycemia. Existing thresholds for defining hypoglycemia are based on observations from clinical trial settings and may not apply to everyday practice. Original Source:- Severe Hypoglycemia Market Research Report 2/2

More Related